Indicators
Indicators
Value
Direction
MACD(12,26,9)
1.829
Buy
RSI(14)
56.898
Neutral
STOCH(KDJ)(9,3,3)
66.052
Neutral
ATR(14)
7.909
Low Volatility
CCI(14)
44.321
Neutral
Williams %R
27.446
Buy
TRIX(12,20)
0.468
Sell
StochRSI(14)
2.423
Sell
ICON PLC
ICLR186.580USD
0.000
Close 12/15, 16:00（ET）Quotes delayed by 15 min
14.25BMarket Cap
25.00P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of ICON PLC
Currency: USD Updated: 2025-12-12Key Insights
ICON PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 17/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 205.69.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ICON PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Buy
Current Rating
205.688
Target Price
+12.95%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ICON PLC Highlights
StrengthsRisks
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 8.28B.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.28B.
Fairly Valued
The company’s latest PE is 25.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.42M shares, decreasing 11.52% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 571.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.06.
Financial Health
Currency: USD Updated: 2025-12-12The current financial score of ICON PLC is 8.85, ranking 31/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.04B, representing a year-over-year increase of 0.63%, while its net profit experienced a year-over-year increase of 98.81%.
Score
Financials
6.46
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.81
ICON PLC's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of ICON PLC is 5.32, ranking 392/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is 25.00, which is 82.46% below the recent high of 45.61 and 45.17% above the recent low of 13.70.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 17/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of ICON PLC is 7.44, ranking 292/404 in the Biotechnology & Medical Research industry. The average price target for ICON PLC is 213.50, with a high of 235.00 and a low of 172.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
18
analysts
Buy
Current Rating
205.688
Target Price
+12.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
ICON PLC
ICLR
18
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of ICON PLC is 9.43, ranking 33/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 200.91 and the support level at 163.18, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
185.606
Buy
MA10
185.269
Buy
MA20
176.957
Buy
MA50
176.545
Buy
MA100
175.217
Buy
MA200
163.724
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of ICON PLC is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 104.00%, representing a quarter-over-quarter increase of 8.89%. The largest institutional shareholder is David G. Herro, holding a total of 2.34M shares, representing 3.07% of shares outstanding, with 8566.10% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Artisan Partners Limited Partnership
Wellington Management Company, LLP
MFS Investment Management
Ninety One UK Limited
Invesco Advisers, Inc.
Templeton Investment Counsel, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of ICON PLC is 6.85, ranking 23/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.25. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.25
VaR
+3.51%
240-Day Maximum Drawdown
+43.11%
240-Day Volatility
+50.57%
Return
Best Daily Return
60 days
+9.89%
120 days
+16.15%
5 years
+16.15%
Worst Daily Return
60 days
-6.63%
120 days
-6.78%
5 years
-21.03%
Sharpe Ratio
60 days
+0.47
120 days
+1.10
5 years
+0.20
Risk Assessment
Maximum Drawdown
240 days
+43.11%
3 years
+63.43%
5 years
+63.43%
Return-to-Drawdown Ratio
240 days
-0.28
3 years
-0.11
5 years
+0.01
Skewness
240 days
+1.25
3 years
+0.02
5 years
+0.13
Volatility
Realised Volatility
240 days
+50.57%
5 years
+40.79%
Standardised True Range
240 days
+3.72%
5 years
+4.15%
Downside Risk-Adjusted Return
120 days
+226.17%
240 days
+226.17%
Maximum Daily Upside Volatility
60 days
+33.30%
Maximum Daily Downside Volatility
60 days
+28.90%
Liquidity
Average Turnover Rate
60 days
+1.65%
120 days
+1.76%
5 years
--
Turnover Deviation
20 days
+5.63%
60 days
+47.18%
120 days
+57.10%
Peer Comparison
Biotechnology & Medical Research
ICON PLC
ICLR
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of ICON PLC?
The TradingKey Stock Score provides a comprehensive assessment of ICON PLC based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of ICON PLC’s performance and outlook.
How do we generate the financial health score of ICON PLC?
To generate the financial health score of ICON PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects ICON PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of ICON PLC.
How do we generate the company valuation score of ICON PLC?
To generate the company valuation score of ICON PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare ICON PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of ICON PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of ICON PLC.
How do we generate the earnings forecast score of ICON PLC?
To calculate the earnings forecast score of ICON PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on ICON PLC’s future.
How do we generate the price momentum score of ICON PLC?
When generating the price momentum score for ICON PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of ICON PLC’s prices. A higher score indicates a more stable short-term price trend for ICON PLC.
How do we generate the institutional confidence score of ICON PLC?
To generate the institutional confidence score of ICON PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about ICON PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of ICON PLC.
How do we generate the risk management score of ICON PLC?
To assess the risk management score of ICON PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of ICON PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of ICON PLC.
